Evidence map›Paper›PMID 39941920›Full record

ReviewCancers2025

Biomarkers for the Evaluation of Immunotherapy in Patients with Cholangiocarcinoma.

Thaleia-Eleftheria Bousou, Panagiotis Sarantis, Ioanna A Anastasiou, Eleni-Myrto Trifylli, Dimitris Liapopoulos, Dimitra Korakaki, Evangelos Koustas, Michalis Katsimpoulas, Michalis V Karamouzis

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Thaleia-Eleftheria BousouUniversity Pathology Clinic, General and Oncology Hospital "Agioi Anargyroi", National and Kapodistrian University of Athens, Timiou Stavrou 14, 145 64 Kifisia, Greece.
Panagiotis SarantisUniversity Pathology Clinic, General and Oncology Hospital "Agioi Anargyroi", National and Kapodistrian University of Athens, Timiou Stavrou 14, 145 64 Kifisia, Greece.ORCID 0000-0001-5848-7905
Ioanna A AnastasiouDiabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, Laiko General Hospital, National and Kapodistrian University of Athens, Agiou Thoma 17, 115 27 Athens, Greece.ORCID 0000-0002-7560-0575
Eleni-Myrto TrifylliGI-Liver Unit, 2nd Department of Internal Medicine, National and Kapodistrian University of Athens, General Hospital of Athens "Hippocratio", 114 Vas Sofias, 115 27 Athens, Greece.
Dimitris LiapopoulosUniversity Pathology Clinic, General and Oncology Hospital "Agioi Anargyroi", National and Kapodistrian University of Athens, Timiou Stavrou 14, 145 64 Kifisia, Greece.
Dimitra KorakakiUniversity Pathology Clinic, General and Oncology Hospital "Agioi Anargyroi", National and Kapodistrian University of Athens, Timiou Stavrou 14, 145 64 Kifisia, Greece.
Evangelos KoustasOncology Department, General Hospital Evangelismos, Ipsilantou 45-47, 106 76 Athens, Greece.
Michalis KatsimpoulasExperimental Surgery Unit, Center of Clinical, Experimental Surgery and Translational Research, Βiοmedical Research Foundation of the Academy of Athens, 4 Soranou Ephessiou, 115 27 Athens, Greece.ORCID 0000-0001-8083-3878
Michalis V KaramouzisUniversity Pathology Clinic, General and Oncology Hospital "Agioi Anargyroi", National and Kapodistrian University of Athens, Timiou Stavrou 14, 145 64 Kifisia, Greece.ORCID 0000-0003-1369-8201

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholangiocarcinoma is a rare primary liver cancer with poor prognosis, due to the advanced stage at the time of diagnosis and limited therapeutic options, with poor response. Chemotherapy remains the standard first-line treatment, but the advent of immunotherapy has recently induced promising results. Given the fact that diagnosis frequency is increasing nowadays and the survival rate remains very low, it is crucial to recognize patients who are suitable for immunotherapy and will have the best response. Different types of biomarkers, such as interleukins, exosomes, mi-RNA, ctDNA, and gene mutations, have been studied for their feasibility, not only for the early diagnosis of biliary tract cancer but also for the determination of responsiveness in treatment. Less frequently, these studies focus on finding and observing biomarkers in patients who receive immunotherapy. This review aims to summarize current knowledge of existing/promising biomarkers in patients with unresectable or metastatic cholangiocarcinoma, treated with immunotherapy as monotherapy, or combined with chemotherapy.

Indexed as

biomarkerscholangiocarcinomaexosomesimmune checkpoint inhibitorsimmunotherapyinterleukinslymphocytes

Identifiers

PMID39941920
PMCPMC11817672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.